496807-11-5
中文名称
sodium:4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoate
英文名称
sodium:4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoate
CAS
496807-11-5
分子式
C24H29NaO5
分子量
420.474
MOL 文件
496807-11-5.mol
496807-11-5 结构式
基本信息
中文别名
(RAC)-贝拉前列素钠贝拉前列素钠盐(非对映异构体混合物)
英文别名
Beraprost sodium (Relative stereochemistry)sodium:4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoate
常见问题列表
生物活性
Beraprost sodium 是一种前列环素类似物，是一种稳定且具有口服活性的 PGI2 前药。Beraprost sodium 是有效的血管扩张剂 (vasodilator)，通过扩张肾血管，改善微循环而具有研究肺动脉高压的潜力。靶点
prodrug of PGI2; Vasodilator
体外研究
Beraprost sodium (0.1, 1.0, and 10.0 μM; 24 hours) treatment leads to a significant increase in the number of tube formation, BPS plays an important role on angiogenic activity. Beraprost sodium (0.1, 1.0, and 10.0 μM; 24 hours) treatment let VE-cadherin at regions of cell–cell contact becomes more abundant and the morphology of endothelial cells tends to be normal compared with those cultured under hypoxia conditions.
体内研究
Beraprost sodium (oral adminstration; 0.6 mg/kg; once daily; 3 or 7 days) can mitigate the development of renal interstitial fibrosis, decrease renal oxidative stress through its potential vasodilation effect, and further prevent renal interstitial fibrosis.
| Animal Model: | 6-8-week-old C57Bl/6J Male Mice |
| Dosage: | 0.6 mg/kg |
| Administration: | Oral adminstration; 0.6 mg/kg; once daily; 3 or 7 days |
| Result: | Mitigated the development of renal interstitial fibrosis. |